Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study

Table 1 Patient demographics and clinical characteristics at SELECTED baseline

Characteristic	Study population
Characteristic	(N = 410)
Age, years, mean (SD)	38 (9)
Female, %	62
No. of relapses in prior study, mean (SD)^a	0.2 (0.5)
Range	0–3
EDSS score, mean (SD)	2.7 (1.3)
Range	0–6
No. of Gd⁺ lesions, mean (SD)	0.2 (1.0)
Range	0–12
Patients with ≥1 Gd⁺ lesion(s), n (%)	40 (10)
No. of T2 hyperintense lesions, mean (SD)	46.3 (36.5)
Range	0–194
T2 hyperintense lesion volume, mm³, median	3868
T1 hypointense lesion volume, mm³, median	751
Months on treatment, median^b	25
Range	<1–45
Doses, mean (SD)	27.7 (10.8)
Median	28.0
Range	1–49

EDSS Expanded Disability Status Scale, Gd ⁺ Gadolinium-enhancing, SC Subcutaneous, SD Standard deviation
^aIncludes all relapses in SELECTION, whether in the treatment period, randomized washout phase, or follow-up period, either confirmed or not confirmed by an independent neurology evaluation committee
^bTime on treatment in days was derived as (date of last dose) – (date of first dose in SELECTED) + 1

ISSN: 1471-2377